A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency.

about

Super-Resolution Imaging and Quantitative Analysis of Membrane Protein/Lipid Raft Clustering Mediated by Cell-Surface Self-Assembly of Hybrid Nanoconjugates Targeted drug delivery for cancer therapy: the other side of antibodies.

P2860

Q36001159-CA3D60D5-F8E7-4044-998E-1C77D3440871 Q38058816-4231A8E8-9766-4A21-A621-1D137C6A57C6

P2860

A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency.

Item

http://www.wikidata.org/entity/Q41791356

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

A new approach to comparing an ...... fts in their lytic efficiency.

@en

type

Item

label

A new approach to comparing an ...... fts in their lytic efficiency.

@en

prefLabel

A new approach to comparing an ...... fts in their lytic efficiency.

@en

P1476

A new approach to comparing an ...... fts in their lytic efficiency.

@en

P2093

Anne Bordron

http://www.w3.org/2001/XMLSchema#string

Christian Berthou

http://www.w3.org/2001/XMLSchema#string

Mariam Hammadi

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

The biology of CD20 and its potential as a target for mAb therapy

Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface

Lipid rafts as a membrane-organizing principle

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.

Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia.

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.

Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.

P304

99-109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jacques-Olivier Pers

Pierre Youinou

P577

2010-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20616960

http://www.w3.org/2001/XMLSchema#string

P932

2895776

http://www.w3.org/2001/XMLSchema#string

A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency.

about

P2860

P2860

A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P407

P478

P50

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P407

P478

P50

P577

P698

P932